此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Zimmer® Maxera™ 髋臼系统在全髋关节置换术中的安全性和性能的 PMCF 研究

2026年9月23日 更新者:Zimmer Biomet

Zimmer® Maxera™ 髋臼系统在全髋关节置换术中的应用。一项多中心、前瞻性、非对照的上市后临床随访研究

This study is a multicenter, prospective, non-controlled post market clinical follow-up study. The objectives of this study are to confirm the safety and performance of the commercially available Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty.

研究概览

详细说明

The objectives of this study are to confirm the safety and performance of the Zimmer Maxera Cup mated with either a BIOLOX® delta or BIOLOX® OPTION femoral head when used in primary total hip arthroplasty.

In total 250 patients will be enrolled into the study at up to 10 sites.All potential study subjects will be required to participate in the Informed Consent Process.

研究类型

观察性的

注册 (实际的)

250

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Montreal、加拿大
        • Center Maisonneuve-Rosemont Hospital
      • Pellenberg、比利时
        • UZ Leuven
      • Perpignan、法国
        • Centre Hospitalier de Perpignan
      • Sydney、澳大利亚
        • The Mater Hospital, Concord Hospital
      • Jämsä、芬兰
        • Jokilaakson terveys oy
      • Liverpool、英国
        • Royal Liverpool and Broadgreen University Teaching Hospitals
      • Delft、荷兰
        • Reinier de Graaf Groep
      • Palma de Mallorca、西班牙
        • Hospital Son Llatzer

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria

描述

Inclusion Criteria:

  • Patient is 18 to 75 years of age, inclusive.

  • Patient is skeletally mature.

  • Patient qualifies for primary unilateral or simultaneous bilateral total hip arthroplasty (THA) based on physical exam and medical history including at least one of the following:

    • Osteoarthritis
    • Avascular necrosis (AVN)
    • Inflammatory arthritis
    • Rheumatoid arthritis with adequate bone quality
    • Post-traumatic arthritis
    • Congenital hip dysplasia.
  • Patient has no history of previous total hip replacement or arthrodesis of the affected hip joint(s). Patient has a Harris Hip Score <70 in the affected hip and a Harris Hip pain rating of moderate, marked, or disabled.

  • Patient is willing and able to provide written informed consent.

  • Patient is willing and able to cooperate in the required post-operative therapy.

  • Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.

  • Patient has participated in the Informed Consent process and has signed the Ethics Committee approved informed consent.

Exclusion Criteria:

  • The patient is:

    • A prisoner
    • Mentally incompetent or unable to understand what participation in the study entails.
    • A known alcohol or drug abuser
    • Anticipated to be non-compliant
  • The patient has a neuromuscular disorder, vascular disorder or other condition that could contribute to prosthesis instability, prosthesis fixation failure, or complications in postoperative care.

  • The patient has local bone tumors and/or cysts in the portion of bone to be retained in the operative hip that could inhibit implant fixation.

  • The patient has insufficient bone stock or poor bone quality to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e. osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be required to assess the presence of adequate bone stock.

  • The patient has rapid disease progression as obvious by joint destruction or bone absorption seen on x-ray.

  • The patient has osteoradionecrosis in the affected hip.

  • The patient has a neuromuscular condition in the ipsilateral or contralateral limb which affects lower limb function.

  • The patient has loss of abductor musculature in the affected hip.

  • The patient has a vascular (large and small vessel disease) insufficiency.

  • The patient has had previous prosthetic hip replacement device (any type, including surface replacement arthroplasty, endoprosthesis, etc.) in the joint to be operated.

  • The patient has had previous girdlestone procedure (resection arthroplasty) or surgical fusion of the hip to be operated.

  • The patient has an acute femoral neck fracture in the operative hip.

  • The patient has had a procedure on the operative hip in the last 6 months (i.e. arthroscopy, ORIF femoral neck fracture, etc).

  • The patient has undergone a total hip replacement, endoprosthesis, or surface arthroplasty of the contralateral (opposite side) hip within the past 6 months regardless of whether the previous hip was enrolled in this clinical study.

  • The patient has a moderate to severe limb length discrepancy greater than 3.2 cm.

  • The patient has an active, old or remote infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.

  • The patient has poor skin coverage around the affected hip joint.

  • The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.

  • The patient is currently receiving, or within the past three months, has received any drug known to potentially interfere with bone/soft tissue healing (e.g. long-term chronic systemic steroid or inhaler steroid therapy).

  • The patient has received an investigational drug or device within the previous 6 months.

  • The patient is known to be pregnant.

  • The patient is unwilling or unable to give informed consent, or to comply with the followup program.

  • The patient is known to have a highly communicable disease that may limit follow-up.

  • The patient has a known sensitivity or allergic reaction to one or more of the implanted materials which include metal and ceramic.

  • The patient is Grade III obese with a Body Mass Index (BMI) > 35.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Patients who received the Maxera Cup

Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
基于移除或预期移除装置并使用 Kaplan-Meier 方法确定的植入物存活率
大体时间:手术后10年
手术后10年

次要结果测量

结果测量
大体时间
基于最终并发症发生的安全性,包括脱臼和修正/移除
大体时间:手术后10年
手术后10年
X 射线评估射线可透性、骨质溶解、肥大、下沉、异位骨化等
大体时间:手术后10年
手术后10年
基于哈里斯髋关节评分的疼痛和功能表现
大体时间:手术后10年
手术后10年
基于 UCLA 评分的疼痛和功能表现
大体时间:手术后10年
手术后10年
受试者的生活质量由 EQ-5D (EuroQoI) 分数决定
大体时间:手术后10年
手术后10年

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Hassan Achakri、Zimmer Biomet

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2013年1月1日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2017年11月30日

首先提交符合 QC 标准的

2017年12月12日

首次发布 (实际的)

2017年12月13日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅